Dr. Yunpeng Yang 杨云鹏
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of lung cancer and nasopharyngeal carcinoma, including chemotherapy, targeted therapy, immunotherapy, and clinical research on new drugs.
Dr. Yang is a Chief Physician at Sun Yat-sen University Cancer Center. Dr. Yang earned a clinical medicine doctorate from Peking Union Medical College in 2012. Research focuses on medical oncology for lung and nasopharyngeal cancers. Dr. Yang has participated in over 30 Phase I–III clinical trials, leads National Natural Science Foundation projects, and has published six papers with impact factors above 10.
Professional roles
- Vice Chair and Secretary-General, Nervous System Tumor Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Immunotherapy Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Chair, Youth Committee of Chemotherapy Committee, Guangdong Anti-Cancer Association
- Standing Committee Member, Cancer Rehabilitation and Palliative Care Professional Committee, Guangdong Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Yunpeng). Papers usually list the name as Yunpeng Yang or Yang Y.
Selected publications
214 papers on PubMed matched by name and affiliation; 30 as first or senior author since 2016. Most recent first- or senior-author papers:
- MedComm (2020), 2026 (senior author): Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study. PubMed 42830869
- Cancer Biol Med, 2026 (senior author): A bispecific EGFR × HER3 antibody-drug conjugate for later-line recurrent or metastatic nasopharyngeal carcinoma: insights from BL-B01D1-303. PubMed 42806904
- J Thorac Oncol, 2026 (senior author): Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial. PubMed 42031067
- J Clin Oncol, 2026 (senior author): Izalontamab Brengitecan in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations Outside of Classical EGFR Mutations: A Phase Ib Study. PubMed 41779981
- JAMA Oncol, 2026 (first author): First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial. PubMed 41746630
- Cell Commun Signal, 2026 (first author): Diverse genomic and transcriptomic heterogeneity in EGFR-mutant lung adenocarcinoma between exon 19 del and exon 21 L858R. PubMed 41826981
- MedComm (2020), 2026 (senior author): Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study. PubMed 42022538
- JAMA Oncol, 2026 (senior author): Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. PubMed 41609753
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion